About Minerva Biotechnologies
Minerva Biotechnologies is a company based in Waltham (United States) founded in 1999. Minerva Biotechnologies has raised $18.86 million across 9 funding rounds from investors including HHS. Minerva Biotechnologies offers products and services including CAR T Therapeutics and AlphaSTEM. Minerva Biotechnologies operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Waltham, United States
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Minerva Biotechnologies Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.86 M (USD)
in 9 rounds
-
Latest Funding Round
$4.52 M (USD), Unspecified
Nov 14, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Minerva Biotechnologies
Minerva Biotechnologies offers a comprehensive portfolio of products and services, including CAR T Therapeutics and AlphaSTEM.
Targets MUC1* positive solid tumors to combat cancer metastasis.
Facilitates efficient iPSC generation and cell expansion for regenerative applications.
People of Minerva Biotechnologies
Unlock access to complete
Unlock access to complete
Funding Insights of Minerva Biotechnologies
Minerva Biotechnologies has successfully raised a total of $18.86M across 9 strategic funding rounds. The most recent funding activity was a Unspecified round of $4.52 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Minerva Biotechnologies
Minerva Biotechnologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Minerva Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Minerva Biotechnologies
Investment portfolio details for Minerva Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Minerva Biotechnologies
Detailed financials for Minerva Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Minerva Biotechnologies Comparisons
Peer comparison for Minerva Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Minerva Biotechnologies
Minerva Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| Locked | Locked | Locked |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
Detailed competitors of Minerva Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Minerva Biotechnologies
Complete news archive for Minerva Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Minerva Biotechnologies
Minerva Biotechnologies was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Minerva Biotechnologies is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Minerva Biotechnologies is a funded company, having raised a total of $18.86M across 9 funding rounds to date.
Minerva Biotechnologies was founded in 1999 and is based in Waltham, United States. Operations center on the biotechnology sector, where cancer immunotherapies are developed to target solid tumors and prevent metastasis. Cell therapies and antibodies form the core of these efforts, aimed at advancing treatments for various cancers through innovative immunological approaches.
Minerva Biotechnologies's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
Minerva Biotechnologies offers CAR T Therapeutics and AlphaSTEM.
Minerva Biotechnologies has 1 investor. Key investors include HHS.